Abstract:We, herein, report the synthesis, characterization, luminescence properties, anticancer, and antibacterial activities of a family of novel half-sandwich iridium(III) complexes of the general formula [(η5-Cpx)Ir(C^N)Cl]PF6- [Cpx = pentamethylcyclopentadienyl (Cp*) or tetramethyl(biphenyl)-cyclopentadienyl (Cpxbiph)] bearing versatile imine-N-heterocyclic carbene ligands. In this complex framework, substituents on four positions could be modulated, which distinguishes this class of complex and provides a large amount of flexibility and opportunity to tune the cytotoxicity of complexes. The X-ray crystal structures of complexes 4 and 10 exhibit the expected "piano-stool" geometry. With the exception of 1, 2, and 11, each complex shows potent cytotoxicity, with IC50 (half-maximum inhibitory concentration) values ranging from 1.99 to 25.86 μM toward A549 human lung cancer cells. First, the effect of four positions bearing different substituents in the complex framework on the anticancer activity, that is, structure-activity relationship, was systematically studied. Complex 8 (IC50 = 1.99 μM) displays the highest anticancer activities, whose cytotoxicity is more than 10-fold higher than that of the clinical platinum drug cisplatin against A549 cancer cells. Second, their chemical reactivity including nucleobases binding, catalytic activity in converting coenzyme NADH to NAD+, reaction with glutathione (GSH), and bovine serum albumin (BSA) binding is investigated. No reaction with nucleobase is observed. However, these iridium(III) complexes bind rapidly to GSH and can catalyze oxidation of NADH to NAD+. In addition, they show moderate binding affinity to BSA and the fluorescence quenching of BSA by the iridium (III) complexes is due to the static quenching. Third, the mode of cell death was also explored through flow cytometry experiments, including cell cycle, apoptosis induction, reactive oxygen species (ROS) and mitochondrial membrane potential. It seems that cell cycle perturbation, apoptosis induction, increase of ROS level and loss of mitochondrial membrane potential together contribute to the anticancer potency of these complexes. Last, the use of confocal microscopy provides insights into the microscopic mechanism that the typical and most active complex 8 enters A549 lung cancer cells mainly through energy-dependent pathway and is located in lysosome. Furthermore, lysosome damage and nuclear morphology were detected by confocal microscopy. Nuclear condensation and apoptotic bodies may finally induce cells apoptosis. Interestingly, complex 8 also shows antibacterial activity against Gram-positive Staphylococcus aureus. This work may provide an alternative and effective strategy to smart design of potent organometallic half-sandwich iridium(III) anticancer drugs.

Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies

Organometallic Iridium Anticancer Complexes

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes

Antitumor Activity of Iridium/ruthenium Complexes Containing Nitro -Substituted Quinoline Ligands in Vivo and in Vitro

Organometallic Iridium(Iii) Cyclopentadienyl Anticancer Complexes Containing C,N-Chelating Ligands

Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.

Potent Half-Sandwich Iridium(III) and Ruthenium(II) Anticancer Complexes Containing a P^O-Chelated Ligand

Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

Synthesis and in Vitro Antitumor Activity of Novel Iridium(iii) Complexes with Enantiopure C2-symmetrical Vicinal Diamine Ligands

Preparation of Novel Rh (III) Half-Sandwich Complexes Bearing 5-Phenyl-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one Ligands, and Their Anti-Cancer Properties

Potent Cyclopentadienyl Iridium Anticancer Complexes Containing CN-chelating Ligands

DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes

Synthesis, Cytotoxicity, and Biomacromolecule Binding: Three Isomers of Nitrosylruthenium Complexes with Bidentate Bioactive Molecules As Co-Ligands

Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes As Lysosome-Targeted Anticancer Agents

Half-sandwich Iridium(iii) Complexes with Α-Picolinic Acid Frameworks and Antitumor Applications.

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Organometallic Half-Sandwich Iridium Anticancer Complexes